Sodium Oxybate (one-nightly)
Narcolepsy
DevelopmentActive
Key Facts
About D&A Pharma
D&A Pharma is a private, European biopharmaceutical company specializing in repurposing and reformulating known drugs for addiction treatment, particularly Alcohol Use Disorders (AUD). Its lead asset, Hopveus®, is a patented solid formulation of sodium oxybate (SMO) designed as an abuse-deterrent outpatient treatment for AUD, which recently had a key EU marketing authorization rejection overturned by the Court of Justice. The company operates with an integrated model covering R&D through commercialization across Europe, targeting niche therapeutic areas often overlooked by larger pharmaceutical firms.
View full company profileTherapeutic Areas
Other Narcolepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| Pitolisant Tablets | lupin | Approved (Tentative) |
| Pitolisant (Wakix®/Ozawade®) | Bioprojet SCR | Approved |
| Narcolepsy Study | Science 37 | Phase 4 |